Compare Torrent Pharma with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs NATCO PHARMA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA NATCO PHARMA TORRENT PHARMA/
NATCO PHARMA
 
P/E (TTM) x 36.9 34.0 108.3% View Chart
P/BV x 9.3 4.8 192.9% View Chart
Dividend Yield % 0.7 0.7 93.5%  

Financials

 TORRENT PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
NATCO PHARMA
Mar-19
TORRENT PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,964849 231.3%   
Low Rs1,245557 223.5%   
Sales per share (Unadj.) Rs453.4573.8 79.0%  
Earnings per share (Unadj.) Rs25.8176.0 14.6%  
Cash flow per share (Unadj.) Rs62.3198.2 31.4%  
Dividends per share (Unadj.) Rs17.006.25 272.0%  
Dividend yield (eoy) %1.10.9 119.2%  
Book value per share (Unadj.) Rs279.2842.7 33.1%  
Shares outstanding (eoy) m169.2236.50 463.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.51.2 288.8%   
Avg P/E ratio x62.24.0 1,558.0%  
P/CF ratio (eoy) x25.83.5 726.2%  
Price / Book Value ratio x5.70.8 688.9%  
Dividend payout %65.93.6 1,856.7%   
Avg Mkt Cap Rs m271,51325,660 1,058.1%   
No. of employees `00013.65.0 274.3%   
Total wages/salary Rs m14,0383,559 394.4%   
Avg. sales/employee Rs Th5,642.64,225.3 133.5%   
Avg. wages/employee Rs Th1,032.4718.0 143.8%   
Avg. net profit/employee Rs Th320.91,295.9 24.8%   
INCOME DATA
Net Sales Rs m76,72820,945 366.3%  
Other income Rs m5711,302 43.8%   
Total revenues Rs m77,29922,247 347.5%   
Gross profit Rs m19,8317,948 249.5%  
Depreciation Rs m6,177810 762.6%   
Interest Rs m5,038193 2,610.1%   
Profit before tax Rs m9,1878,247 111.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,2541,823 68.8%   
Profit after tax Rs m4,3636,424 67.9%  
Gross profit margin %25.837.9 68.1%  
Effective tax rate %13.622.1 61.7%   
Net profit margin %5.730.7 18.5%  
BALANCE SHEET DATA
Current assets Rs m50,37523,472 214.6%   
Current liabilities Rs m51,6537,287 708.8%   
Net working cap to sales %-1.777.3 -2.2%  
Current ratio x1.03.2 30.3%  
Inventory Days Days9292 99.9%  
Debtors Days Days6888 77.4%  
Net fixed assets Rs m83,64818,648 448.6%   
Share capital Rs m846365 231.8%   
"Free" reserves Rs m46,39734,525 134.4%   
Net worth Rs m47,24430,760 153.6%   
Long term debt Rs m39,1290-   
Total assets Rs m141,20943,031 328.2%  
Interest coverage x2.843.7 6.5%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.50.5 111.6%   
Return on assets %6.715.4 43.3%  
Return on equity %9.220.9 44.2%  
Return on capital %12.327.4 45.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,10311,536 191.6%   
Fx outflow Rs m5,5222,939 187.9%   
Net fx Rs m16,5818,597 192.9%   
CASH FLOW
From Operations Rs m17,9816,688 268.9%  
From Investments Rs m-2,413-6,122 39.4%  
From Financial Activity Rs m-13,145-509 2,582.4%  
Net Cashflow Rs m2,38066 3,606.4%  

Share Holding

Indian Promoters % 71.5 52.0 137.4%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 7.0 7.8 89.5%  
FIIs % 12.6 16.6 75.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 26.0 33.8%  
Shareholders   26,511 25,395 104.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   PANACEA BIOTECH  BIOCON   J.B.CHEMICALS  JUBILANT PHARMOVA   AJANTA PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Warning About Bubbles(Fast Profits Daily)

Apr 16, 2021

Those who don't learn from financial history are doomed to lose their money.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Apr 20, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS